• Name:Fubin Li

  • Office Location:280 South Chongqing Road, Room 1008, West #5 Building, Shanghai, China 200025

  • Telephone:86-21-54592183



1997-2001 Fudan University B.S.

2002-2008 The City University of New York (CUNY) Ph.D


2009-2012 The Rockefeller University     Postdoctoral Associate
2012-2013 The Rockefeller University     Research Associate
2013- Shanghai Jiao Tong University School of Medicine     Principal Investigator
2014- The Rockefeller University     Member of the Adjunct Faculty

Research Interests

The lab is mainly interested in two research subjects: (1) how the in vivo activities of cancer immunotherapeutic antibodies are regulated and can be optimized; (2) how B cell development and differentiation are regulated.

Among several ongoing research projects in the lab, we are studying how the interaction between agonistic anti-tumor antibodies and Fcγ receptors impacts on their in vivo activities.

Fcγ receptors have complex interplay with immunoglobulins and regulate both afferent and efferent immune responses. Fcγ receptors are also critical mediators and regulators of therapeutic antibodies’ activities. The research of the lab is focused on the function of Fcγ receptors in immunoregulation and immunotherapy and the underlying molecular mechanism, such as their regulation on B cell response, and on the activities of different classes of antibodies including agonistic antibodies.


I.        National Overseas High Level Young Tanlents Program, team leader;

II.       Professor of Special Appointment at Shanghai Institutions of Higher Learning program, team leader;

III.      National Natural Science Foundation of China, general program 31370934, The Mechanism of driving the anti-tumor activities of agonistic anti-TNFR superfamily member antibodies by inhibitory Fcgamma receptor, 2014/01 - 2017/12、team leader;

IV.      Ministry of Science and Technology of China, program 2014CB943600, Post-transcriptional regulation in lymphocyte development, 2014/01 - 2018/08, team member;

V.       National Natural Science Foundation of China, National Science Fund for Excellent Young Scientists program 31422020, Targeted therapeutic molecules based on antibody Fc, 2015/01 - 2017/12, team leader

VI.    Shanghai Municipal Education Commission and Shanghai Education Development Foundation, Shu Guang Scholar, Study of the antitumor activity and mechanism of agonistic Fc-CD40L fusion protein, 2015/01-2017/12, team leader

VII.   Innovent Biologics, Inc; Hengrui Medicine, Agonistic antibody, Lateral project, 2016/01-2019/08, team leader

VIII.  Ministry of Science and Technology of China, 2018ZX10302301-002, The development of diagnosis strategies and products based on specific immune responses to new M. Tuberculosis antigens, 2018/01-2020/12, team leader

IX.   Shanghai Science and Technology Committee (STCSM), STCSM-Experimental Animal Grant, The development and application of mice humanized for the target and Fc receptors of monoclonal antibodies, 2018/05-2021/04, team leader

X.    National Natural Science Foundation of China, 31870924, The impact and mechanism of action of IgG subclass on the pathogenicity of Dsg1-specific autoantibodies in pemphigus foliaceus, 2019/01-2022/12, team leader

XI.   National Natural Science Foundation of China, 31861143030, Targeting TIGIT-PVR interactions for cancer immunotherapy using monoclonal, 2019/01-2021/12, team leader

XII.  Shanghai Science and Technology Committee (STCSM), STCSM-Preclinical studies of biological and chemical drugs, Preclinical study of novel agonistic antitumor CD40 antibody, 2019/04-2022/03, team leader

XIII.  National Natural Science Foundation of China,  82030043, Elucidation of the modes of action and immunothereapeutic effector pathways of monoclonal anti-OX40 antibodies and optimization of antibody design, 2021/01-2025/12, team leader

1.  Dahan, R., B. C. Barnhart, F. Li, A. P. Yamniuk, A. Korman, J.V. Ravetch. .Therapeutic activity of agonistic, human anti-CD40 monoclonal Abs requires ive FcγR-engagement..Cancer Cell ,2016,29(6):820-831.   [Link]

2.  Li M*, Lazorchak AS*, Ouyang X, Zhang H, Liu H, Arojo OA, Yan L, Jin J, Han Y, Qu G, Fu Y, Xu X, Liu X, Zhang W, Yang Z, Ruan C, Wang Q, Liu D, Huang C, Lu L, Jiang S, Li, F#, Su, B#.Sin1/mTORC2 regulates B cell growth and metabolism via mTORC1 and Myc activation.Cellular & Molecular Immunology,2019,16:757–769.   [Link]

3.  Peng C, Hu Q, Yang F, Zhang H, Li F, Huang C.BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.J Immunol,2019,202(3):704-713.   [Link]

4.  Wenqian Zhang*, Huihui Zhang*, Shujun Liu, Fucan Xia, Zijian Kang, Yan Zhang, Yaoyang Liu, Hui Xiao, Lei Chen, Chuanxin Huang, Nan Shen, Huji Xu, Fubin Li.Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus.Proceedings of the National Academy of Sciences of the United States of America,2019,116(37):18550-18560.   [Link]

5.  Xiaobo Liu*, Yingjie Zhao*, Huan Shi*, Yan Zhang, Xueying Yin, Mingdong Liu, Huihui Zhang, Yongning He, Boxun Lu, Tengchuan Jin, Fubin Li.Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.Nature Communications,2019,10(1): 4206.   [Link]

6.  Rongqing Zhao, Huihui Zhang, Yan Zhang, Dan Li, Chuanxin Huang, Fubin Li.In Vivo Screen Identifies Zdhhc2 As a Critical Regulator of Germinal Center B Cell Differentiation.Frontiers in Immunology,2020,11:1025.   [Link]

7.  Georgoudaki, A.M., K. Prokopec, E. Hellqvist, V. Boura, J. Östling, S. Sohn, R.A. Harris, M. Rantalainen, D. Klevebring, M. Sund, J. Fuxe, C. Rolny, F. Li, J.V. Ravetch, M.C.I. Karlsson. .Reprogramming tumor associated macrophages by antibody targeting inhibits cancer progression and metastasis. .Cell Reports ,2016,15(9):2000-11.   [Link]

8.  Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T, Shi H, Liu M, Du M, Taylor PR, Zhu HH, Chen J, Meng G, Li F, Chen C, Zhang Y, Jia XM, Lin X, Zhang X, Pearlman E, Li X, Feng GS, Xiao H.Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.Nature Immunology,2015,16:642-52.   [Link]

9.  Li F,P.Smith,J.V.Ravetch.Inhibitory Fcgamma Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms..Journal of immunology,2014,192:3021-8.   [Link]

10.  Li, F., J. V. Ravetch.Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo.Proceedings of the National Academy of Sciences of the United States of America,2013,110: 19501-19506.   [Link]

11.  Simpson, T. R., F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. .Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.The Journal of experimental medicine ,2013,210: 1695-1710.   [Link]

12.  Li, F., J. V. Ravetch.Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement.Proceedings of the National Academy of Sciences of the United States of America ,2012,109: 10966-10971.   [Link]

13.  Li, F., and J. V. Ravetch.A general requirement for FcgammaRIIB co-engagement of agonistic anti-TNFR antibodies.Cell cycle ,2012,11: 3343-3344.   [Link]

14.  Smith, P., D.J. Dilillo, S. Bournazos, F. Li, and J.V. Ravetch.Mouse model recapitulating human Fcgamma receptor structural and functional diversity.Proceedings of the National Academy of Sciences of the United States of America,2012,109:6181-6186.   [Link]

15.  Li, F., and J.V. Ravetch.Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.Science ,2011,333:1030-1034.   [Link]

16.  Li, F., Y. Yan, J. Pieretti, D.A. Feldman, and L.A. Eckhardt.Comparison of identical and functional Igh alleles reveals a nonessential role for Emu in somatic hypermutation and class-switch recombination.Journal of immunology ,2010,185:6049-6057.   [Link]

17.  Li, F., and L.A. Eckhardt.A role for the IgH intronic enhancer E mu in enforcing allelic exclusion.The Journal of experimental medicine ,2009,206:153-167.   [Link]

18.  Zhang, B., A. Alaie-Petrillo, M. Kon, F. Li, and L.A. Eckhardt.Transcription of a productively rearranged Ig VDJC alpha does not require the presence of HS4 in the IgH 3 regulatory region.Journal of immunology ,2007,178:6297-6306.   [Link]

19.  Romov, P.A., F. Li, P.N. Lipke, S.L. Epstein, and W.G. Qiu.Comparative genomics reveals long, evolutionarily conserved, low-complexity islands in yeast proteins.Journal of molecular evolution,2006,63:415-425.   [Link]

20.  Garrett, F.E., A.V. Emelyanov, M.A. Sepulveda, P. Flanagan, S. Volpi, F. Li, D. Loukinov, L.A. Eckhardt, V.V. Lobanenkov, and B.K. Birshtein.Chromatin architecture near a potential 3 end of the igh locus involves modular regulation of histone modifications during B-Cell development and in vivo occupancy at CTCF sites.Molecular and cellular biology ,2005,25:1511-1525.   [Link]


Mi Zhang

M.S Candidate (Class 2019)

Shujun Liu

Ph.D. Candidate (Class 2016)

Shihao Tian

Ph.D. Candidate (Class 2018)

Yan Zhang,Ph.D.

Assistant Research Fellow

Yingjie Zhao

M.S Candidate (Class 2015)

Yanxia Bi

Ph.D. Candidate (Class 2015)

Man Li

Ph.D. Candidate (Class 2014)

Rongqing Zhao

Ph.D. Candidate (Class 2014)

Huan Shi

M.S Candidate (Class 2013)

Wenqian Zhang

Ph.D. Candidate (Class 2013)

Xiaobo Liu


Huihui Zhang,Ph.D.

Associate Research Fellow

Lab Location:280 South Chongqing Road, Room 1011, West #5 Building, Shanghai, China 200025



Copyright 2016. Shanghai Institute of Immunology,Shanghai Jiao Tong University School of Medicine.All Rights Reserved.